 | |
| Clinical data | |
|---|---|
| Trade names | Vyondys 53 |
| Other names | SRP-4053 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antisense oligonucleotide |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C305H481N138O112P25 |
| Molar mass | 8647.401 g·mol−1 |
Golodirsen, sold under the brand name Vyondys 53, is a medication used for the treatment of Duchenne muscular dystrophy.[2] It is an antisense oligonucleotide medication of phosphorodiamidate morpholino oligomer (PMO) chemistry.[1][3]
The most common side effects include headache, fever, fall, cough, vomiting, abdominal pain, cold symptoms (nasopharyngitis) and nausea.[2][1]
- ^ a b c "Vyondys 53- golodirsen injection". DailyMed. 31 March 2020. Archived from the original on 23 October 2020. Retrieved 6 August 2020.
- ^ a b Cite error: The named reference
FDA PRwas invoked but never defined (see the help page). - ^ Anwar S, Yokota T (August 2020). "Golodirsen for Duchenne muscular dystrophy". Drugs of Today. 56 (8): 491–504. doi:10.1358/dot.2020.56.8.3159186. PMID 33025945. S2CID 222183389.